What versions of larotrectinib are there

Introduction: Larotrectinib mainly targets patients with solid tumors carrying NTRK gene fusions, showing significant therapeutic potential and efficacy. Currently, there are multiple versions of larotrectinib on the market, mainly including original drugs and generic drugs. Each type is different according to dosage form, specifications and origin.

Original drug version

Larotinib capsules from Bayer in Germany: As the original drug of , the capsules produced by Bayer in Germany are available in two specifications - 25mg56 tablets and 100mg56 tablets to meet the treatment needs of different patients. The prices are relatively high, at 15,340$ and 52,000$ per box respectively, reflecting the research and development costs and market positioning of the original drugs.

Germany's Bayer larotrectinib oral solution: In order to facilitate the use of specific patient groups (such as children or those with dysphagia), Bayer has also launched a 20mg/ml oral solution dosage form, priced at 18,228$ per box, demonstrating its consideration of patient convenience.

Generic version

With the recognition of the efficacy of larotrectinib, pharmaceutical companies in many countries have begun to produce generic drugs to benefit more patients at lower prices.

Bangladesh Everest: The specification is 100mg*30 tablets, and the price is about $4520 per box. It is one of the more cost-effective choices.

Bangladesh Yaopin International: It also provides 100mg*30 tablets, but the price is more affordable, about $4,000 per box, further reducing the financial burden on patients.

Lucius, Laos: The generic version of larotinib produced in Laos has the same specification of 100mg*30 tablets, and its price is only $1,950 per box. It is one of the lowest-priced versions on the market, providing new treatment hope for patients with limited financial conditions.

Drug Interaction Overview

Effects of Other Drugs on Larotrectinib:

CYP3A4 Inhibitors: Strong and moderate CYP3A4 inhibitors may increase larotrectinib plasma concentrations, thereby increasing the risk of adverse reactions. Therefore, concurrent use with strong CYP3A4 inhibitors (such as itraconazole, ketoconazole, etc.) should be avoided, and the dose of larotrectinib needs to be adjusted if necessary.

CYP3A4 inducers: Strong and moderate CYP3A4 inducers can reduce the plasma concentration of larotrectinib and affect its efficacy. Therefore, coadministration with strong CYP3A4 inducers (such as rifampicin, phenytoin, etc.) should also be avoided, or the dose should be adjusted when unavoidable.

Effects of larotinib on other drugs:

Sensitive CYP3A4 substrates: Larotinib may increase the plasma concentration of sensitive CYP3A4 substrates (such as diazepam, lorazepam, etc.), thereby increasing the risk of adverse reactions. Therefore, concurrent use with these drugs should be avoided or used with caution, and patient response should be closely monitored